Close Menu

People in the News

Feb 21, 2020

LifeOmic: Ed Simcox

Precision medicine software firm LifeOmic has named Ed Simcox as its new chief strategy officer. Simcox joins LifeOmic from the US Department of Health and Human Services, where he served as chief technology officer and acting chief information officer. Prior to this, Simcox was director of US health care strategy, partnerships, and product development for AT&T. He also served as healthcare practice leader at Logicalis US, a global IT firm.

Feb 21, 2020

Predictive Oncology: Dan Handley

Predictive Oncology has appointed Dan Handley to its board of directors. Handley is a professor and director of the Clinical and Translational Genome Research Institute of Southern California University. Previously, he was chief scientific officer of the Clinical and Translational Genome Research Institute, a Florida-based non-profit. He also previously served as chief scientific officer for Advanced Healthcare Technology Solutions; as a senior researcher at Procter & Gamble; a senior administrator, researcher, and laboratory manager at the David Geffen UCLA School of Medicine; and as a founding biotechnology inventor for the National Genetics Institute.

Feb 20, 2020

Sophia Genetics: Troy Cox

Sophia Genetics has named former Foundation Medicine CEO Troy Cox chairman of its board of directors, effective March 1. Cox will replace Antoine Duchateau, whom the company said will remain on the board. Cox, who also has held executive positions at US BioOncology and Genentech, joined the Sophia Genetics board in July 2019. 

Feb 19, 2020

Waters: Francis Kim

Francis Kim has resigned from his position as senior VP, global operations of Waters, effective March 16, 2020. He joined Waters in 2017 after 20 years at Medtronic, where he was VP of quality, Restorative Therapies Group.

Feb 18, 2020

Laboratory for Advanced Medicine: Benjamin Oyler

Laboratory for Advanced Medicine has appointed Benjamin Oyler as its chief operating officer. Oyler previously served as VP of strategy and business operations at Ancestry DNA and AncestryHealth. Prior to Ancestry, Oyler worked on several product launches, building operations, and manufacturing capabilities in the US and Asia. 

Feb 14, 2020

Biocept: Cory Dunn

Biocept has promoted Cory Dunn to Senior VP of commercial operations, succeeding Edwin Hendrick, who resigned to pursue other endeavors. Dunn previously served as Biocept's VP of commercial operations, beginning in October 2018. Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (presently Decipher Biosciences), PLUS Diagnostics (presently Inform Diagnostics) and Genoptix.  She holds an MA in education from Stanford University, and an MS in biology and BS in Biochemistry and Cell Biology from the University of California, San Diego.

Feb 13, 2020

Sophia Genetics: Philippe Menu

Sophia Genetics has named Philippe Menu as chief medical officer. Menu joined the Swiss bioinformatics company from McKinsey, where he was co-leader of the McKinsey Cancer Center. A physician with a PhD in molecular biology, Menu primarily advised pharmaceutical and biotech companies in the development of new therapies and diagnostics in oncology and rare diseases. At Sophia, he will lead the firm's medical strategy.

Feb 13, 2020

Wamberg Genomic Advisers: Robert Green

Wamberg Genomic Advisers has appointed Robert Green to its advisory board. A medical geneticist and physician-scientist, Green directs the G2P Research Program in the Division of Genetics at Brigham and Women's Hospital and Harvard Medical School. He is principal investigator of the MedSeq project, an NIH-funded randomized trial to explore the use of whole-genome sequencing in the clinical practice of medicine, and co-leads the BabySeq project, evaluating sequencing in newborns.

Green also directs the recently established Brigham Preventive Genomics Clinic, which offers comprehensive genome sequencing and interpretation to healthy adults and their children. He was the lead author of the published recommendations from the American College of Medical Genetics and Genomics for management of incidental findings in clinical sequencing. As an advisor to Wamberg, Green will help guide the firm in its further development of product offerings and programs as well as lead the selection of future advisory board members from the scientific community. 

Feb 12, 2020

PreludeDx: Edwin Hendrick

PreludeDx has appointed Edwin Hendrick as the company's chief commercial officer. He has more than 30 years of related commercial experience and was most recently at Biocept. Before that, he was at Decipher Biosciences, formerly called GenomeDx, and at Plus Diagnostics. Laguna Hills, California-based PreludeDx's main product is the DCISionRT risk assessment test for patients with ductal carcinoma in situ

Feb 12, 2020

Decipher Biosciences: Robert Epstein, Kathy Hibbs

Decipher Biosciences has appointed Robert Epstein and Kathy Hibbs to its board of directors. Epstein was also elected as the firm's chairman.

Epstein is CEO and cofounder of Epstein Health. He also serves on the board of directors at Illumina, Fate Therapeutics, Veracyte, and Proteus Digital Health. Epstein previously served as president at Medco-UBC from 2010 to 2012. From 1997 to 2010, he held the role of Medco's chief medical officer. He has also served on the boards of directors of the Drug Information Association and the International Society of Quality of Life. In addition, he has served on the Centers for Disease Control and Prevention's Evaluation of Genomic Application in Practice & Prevention Stakeholder Committee, as well as on the Agency for Healthcare Research and Quality Centers for Education and Research on Therapeutics Committee.

Hibbs has served as chief legal and regulatory officer for 23andMe since 2014. She has also served as a member of the Fast Company Impact Council since April 2019 and as a member of the board of directors of Cadex Genomics since Oct 2019. Prior to 23andMe, she was senior VP and general counsel at Genomic Health.

Feb 10, 2020

GenMark Diagnostics: Scott Mendel, Hany Massarany, Kevin O’Boyle, James Fox

GenMark Diagnostics has appointed Scott Mendel, its chief operating officer, as interim president and CEO, effective immediately. Hany Massarany has stepped down as president and CEO and as a member of the company’s board of directors, also effective immediately. GenMark said it has commenced a search to identify a permanent CEO.

The firm appointed Kevin O’Boyle as chairman of the board. James Fox, GenMark’s prior chairman, will remain on the board as a non-executive director.

Feb 07, 2020

Pacific Biosciences: Michael Phillips, Denis Zaccarin

Pacific Biosciences announced that Senior VP of R&D Michael Phillips will retire, effective April 1, 2020.

Phillips joined the company in 2005 and oversaw development of all sequencing systems, including the PacBio RS, launched in 2011; RS II, launched in 2013; Sequel, launched in 2015; and Sequel II, launched in 2019.

Denis Zaccarin, PacBio's VP of semiconductor integrated devices, will succeed Phillips as the head of R&D. Zaccarin, who holds a doctorate, joined the firm in 2004 and oversaw designs and development of SMRT cells.

Feb 06, 2020

Illumina: Scott Gottlieb

Illumina has appointed Scott Gottlieb to its board of directors. Gottlieb is currently a special partner at New Enterprises Associates and a resident fellow at the American Enterprise Institute. He previously served as the 23rd commissioner of the US Food and Drug Administration form 2017 to 2019. Prior to joining the US FDA as commissioner, Gottlieb was a clinical assistant professor at the New York University School of Medicine. 

Feb 05, 2020

Luna Genetics: Arthur Beaudet

Arthur Beaudet has retired from Baylor College of Medicine, where he was a professor of molecular and human genetics, molecular and cellular biology, and pediatrics. He is now full-time CEO of Luna Genetics, a startup he cofounded in 2018 that aims to develop fetal cell-based noninvasive prenatal tests.

Feb 05, 2020

Aperiomics: Elizabeth Pyle

Aperiomics has appointed Elizabeth Pyle as chief operating officer. Prior to joining Aperiomics, she directed the University of Virginia's National Sciences Entrepreneurship Program and founded consulting firm Pyle & Associates. Aperiomics leverages metagenomic sequencing and big data to identify every known bacteria, virus, fungus, and parasite. 

Feb 05, 2020

NeoGenomics: Kathryn McKenzie, William Bonello, Douglas Brown

NeoGenomics announced three leadership appointments: Kathryn McKenzie as CFO, William Bonello as president of the informatics division, and Douglas Brown as chief strategy and corporate development officer. McKenzie was previously the VP of finance and chief accounting officer after joining NeoGenomics in 2017. She was also the assistant controller and director of financial reporting and treasury at Chico's FAS, and worked at Ernst and Young. 

Bonello was previously the chief strategy and corporate development officer at NeoGenomics and will continue as director of investor relations, which he's been since 2018. Before joining NeoGenomics, he was a healthcare equity analyst at Craig-Hallum and senior VP for investor relations at Laboratory Corporation of America. 

Brown is joining NeoGenomics from SVB Leerink, where he was senior managing director. He recently advised NeoGenomics on the acquisition of GenOptix and the oncology assets of Human Longevity. 

Feb 04, 2020

DxTerity Diagnostics: Brett Swansiger

DxTerity Diagnostics has appointed Brett Swansiger as chief commercialization officer. Prior to DxTerity, Swansiger held multiple positions at MDxHealth, including VP of managed care and payor strategy. Before MDxHealth, he served as VP of managed care and Asia market acess for Agendia. Prior to Agendia, Swansiger help multiple positions at Prometheus Laboratories. 

Jan 31, 2020

RedShiftBio: Julien Bradley

RedShift BioAnalytics (RedShiftBio) , a provider of analytical solutions for protein characterization in biotherapeutic development, has appointed Julien Bradley as CEO. Bradley most recently served as vice president of marketing, corporate development and strategy at Quanterix, where he also previously served as VP of marketing and sales operations. He has also held senior roles at Phosphorus, OvaScience, and Thermo Fisher Scientific.

Jan 28, 2020

Interpace Biosciences: Fortunato Ron Rocca, Felice Schnoll-Sussman, James Early, Fred Knechtel, Jeff Salzman

Interpace Biosciences has appointed Fortunato Ron Rocca as a class II director. Rocca will serve on the firm's board as a non-employee director. Concurrently with the appointment, Felice Schnoll-Sussman has resigned from Interpace Bio's board. Rocca currently serves as president and CEO of Exagen.

Interpace Bio also said that CFO and Treasurer James Early is retiring from the firm. Early will be replaced by Fred Knechtel, who previously served as CFO at Genewiz. 

Interpace Bio has also appointed Jeff Salzman as VP of managed care and payor relations. Prior to Interpace Bio, Salzman held roles at Quest Diagnostics, Monogram Biosciences, Vermillion, and most recently at CareDx. 

Jan 28, 2020

Personal Genome Diagnostics: Megan Bailey

Personal Genome Diagnostics has appointed Megan Bailey as chief commercial officer. Bailey joined the firm as VP of marketing in 2018. Prior to PGDx, Bailey spent more than 14 years at Roche in various sales and marketing roles, most recently as senior director of commercial operations. 

Jan 27, 2020

BioSoft Integrators: Debbie Bowers

BioSoft Integrators, a provider of informatics solutions for life science research and clinical diagnostic laboratories, has appointed Debbie Bowers as president and chief commercial officer. Bowers joined BioSoft as vice president of commercial operations in November 2017. Prior to joining BioSoft, she was VP of robotic operations at Hamilton Robotics. Prior to that, she was a VP of business development at Invetech, a then Danaher company that provides development and contract manufacturing services to global research, clinical, and consumer companies.

Jan 27, 2020

Biocartis: Ewoud Welten

Biocartis announced that CFO Ewoud Welten has decided to resign from the firm to pursue an opportunity in the Netherlands. Having served at Biocartis for about five years, Welten will stay with the firm until April. Biocartis has begun a selection process to recruit a new CFO

Jan 27, 2020

QuantuMDx: Jonathan O'Halloran, Neil Butler, Elaine Warburton, John Burn

QuantuMDx announced the appointments of Jonathan O'Halloran as CEO and Neil Butler as chairman of the board as the company begins its transition to commercialization.

A cofounder and former CSO of the firm, O'Halloran invented many of its proprietary technologies. He has a background in genetics and genomics and has been focusing on tuberculosis and antimicrobial resistance for the past 12 years.

QuantuMDx appointed Neil Butler to its board as a non-executive director in July 2019. He also serves on the boards of Nidor Dx, Radisens, and Spectromics and previously served as chair and non-executive director for Binx Health and Genomic Vision.

QuantuMDx said its CEO and Cofounder Elaine Warburton will move into the role of non-executive director and continue to support QuantuMDx in an ambassadorial role, including with key strategic projects. John Burn will step back as chairman, a role he had undertaken upon the company's inception in 2008, and become vice-chairman of the board of directors.

Jan 24, 2020

Guardant Health: Kumud Kalia

Guardant Health has appointed Kumud Kalia as its new chief information officer. In the role, he will lead the company's enterprise applications, information technology, and security teams. Kalia was most recently chief information and technology officer at Cylance, and previously served the same role at Akamai Technologies. He received Computerworld's "best in class" recognition among its 100 premier information technology leaders and has led teams that have won CIO100, CTO25, and other industry awards. He holds an honors degree in electronic engineering from Bangor University, is a chartered engineer, and is a fellow of both the Institution of Engineering and Technology and the British Computer Society.

Jan 23, 2020

Agilent Technologies: Mark Doak, Padriag McDonnell

Agilent Technologies said this week that Mark Doak will retire as senior VP of the firm and president of Agilent CrossLab Group, effective May 1, 2020. Agilent has named Padraig McDonnell, currently VP and general manager of the firm's chemistries and supplies division, to succeed Doak. McDonnell has served in various roles at Agilent for 22 years.  

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.